# Septerna, Inc.: overview SEPN · Nasdaq · CIK 1984086 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sepn.md) · [Financials](/companies/sepn/financials.md) · [Filings](/companies/sepn/filings.md) · [Insiders](/companies/sepn/insiders.md) Latest reported revenue: [$26.7m](/filings/0001193125-26-342353.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-342353). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001193125-25-273375.md) | [0.2 d](/filings/0001193125-26-098507.md) | [0.2](/filings/0001193125-26-216759.md) | [0.1](/filings/0001193125-26-342353.md) | [21.5](/filings/0001193125-25-273375.md) | [24.1 d](/filings/0001193125-26-098507.md) | [26.5](/filings/0001193125-26-216759.md) | [26.7](/filings/0001193125-26-342353.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(12812.5%)](/filings/0001193125-25-273375.md) | [(11659.4%) d](/filings/0001193125-26-098507.md) | [(11831.1%)](/filings/0001193125-26-216759.md) | [(24351.3%)](/filings/0001193125-26-342353.md) | [12.2%](/filings/0001193125-25-273375.md) | [(66.4%) d](/filings/0001193125-26-098507.md) | [(50.1%)](/filings/0001193125-26-216759.md) | [(62.9%)](/filings/0001193125-26-342353.md) | | Net margin | % | [(11660.8%)](/filings/0001193125-25-273375.md) | [(9749.1%) d](/filings/0001193125-26-098507.md) | [(9806.4%)](/filings/0001193125-26-342353.md) | [(20872.3%)](/filings/0001193125-26-342353.md) | [38.0%](/filings/0001193125-25-273375.md) | [(44.5%) d](/filings/0001193125-26-098507.md) | [(32.6%)](/filings/0001193125-26-342353.md) | [(48.7%)](/filings/0001193125-26-342353.md) | | Diluted EPS | $ per share | [(8.40)](/filings/0001193125-25-273375.md) | not reported | [(0.49)](/filings/0001193125-26-216759.md) | [(0.56)](/filings/0001193125-26-342353.md) | [0.18](/filings/0001193125-25-273375.md) | not reported | [(0.19)](/filings/0001193125-26-216759.md) | [(0.29)](/filings/0001193125-26-342353.md) | | Free cash flow | $m | [(17.4) d](/filings/0001193125-25-273375.md) | [(21.6) d](/filings/0001193125-26-098507.md) | [(23.7)](/filings/0001193125-26-216759.md) | [(20.3) d](/filings/0001193125-26-342353.md) | [169 d](/filings/0001193125-25-273375.md) | [(15.1) d](/filings/0001193125-26-098507.md) | [(26.5)](/filings/0001193125-26-216759.md) | [(22.2) d](/filings/0001193125-26-342353.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0000950170-25-045745.md) | [1.1](/filings/0001193125-26-098507.md) | [46.0](/filings/0001193125-26-098507.md) | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | [1374.2%](/filings/0000950170-25-045745.md) | [(7518.4%)](/filings/0001193125-26-098507.md) | [(148.6%)](/filings/0001193125-26-098507.md) | | Net margin | % | [2768.2%](/filings/0000950170-25-045745.md) | [(6678.9%)](/filings/0001193125-26-098507.md) | [(106.4%)](/filings/0001193125-26-098507.md) | | Diluted EPS | $ per share | [0.29](/filings/0000950170-25-045745.md) | [(7.26)](/filings/0001193125-26-098507.md) | [(1.10)](/filings/0001193125-26-098507.md) | | Free cash flow | $m | [(41.6)](/filings/0000950170-25-045745.md) | [(69.6)](/filings/0001193125-26-098507.md) | [110](/filings/0001193125-26-098507.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sepn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $234.3m | 6,995,858 | | Unchanged | | [TRV GP V, LLC](/funds/1990717.md) | 2026-06-30 | $208.2m | 6,215,591 | | Unchanged | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $148.5m | 4,433,058 | | Added +37,486 | | [TRV GP VI, LLC](/funds/1990716.md) | 2026-06-30 | $141.0m | 4,211,659 | | Unchanged | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $105.5m | 3,149,128 | | Unchanged | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $102.6m | 3,062,766 | | Added +156,339 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $64.7m | 1,932,088 | | Added +109,914 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $63.6m | 1,900,000 | | Reduced −100,000 | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $44.8m | 1,337,500 | | Unchanged | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $43.7m | 1,307,500 | | Not compared | ## Recent filings [All 169 filings](/companies/sepn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-25 | 12:15 ET | [8-K](/filings/0001193125-26-364210.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-364210 | | 2026-08-14 | 21:14 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000228.md) | Ownership report, active investor, amended | 0001346824-26-000228 | | 2026-08-10 | 20:06 ET | [10-Q](/filings/0001193125-26-342353.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342353 | | 2026-08-10 | 20:03 ET | [8-K](/filings/0001193125-26-342328.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342328 | | 2026-06-30 | 20:30 ET | [8-K](/filings/0001193125-26-290649.md) | 5.07 Shareholder vote results | 0001193125-26-290649 | | 2026-05-11 | 20:08 ET | [10-Q](/filings/0001193125-26-216759.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216759 | | 2026-05-11 | 20:05 ET | [8-K](/filings/0001193125-26-216723.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216723 | | 2026-04-30 | 20:21 ET | [DEF 14A](/filings/0001193125-26-197404.md) | Proxy statement, period 2026-04-30 | 0001193125-26-197404 | | 2026-04-13 | 12:30 ET | [8-K](/filings/0001193125-26-152045.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-152045 | | 2026-03-09 | 20:11 ET | [10-K](/filings/0001193125-26-098507.md) | Annual report, period 2025-12-31 | 0001193125-26-098507 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-098507.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7ee2d869-9f58-406a-92d4-62055c96430f) ## About the filer - CIK: 1984086 - Tickers: SEPN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.